Literature DB >> 15526080

Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.

Paul N Morris1, Benjamin J Dunmore, Amir Tadros, Douglas A Marchuk, Diane C Darland, Patricia A D'Amore, Nicholas P J Brindle.   

Abstract

Tie2 is expressed predominantly in endothelial cells and is required for blood vessel formation and maintenance. A missense mutation resulting in an R to W substitution in the kinase domain of Tie2 co-segregates with an autosomal dominantly inherited form of vascular dysmorphogenesis, venous malformation (VM). The mechanism by which this activating mutation leads to vessel dysmorphogenesis in VM is not known. Here we examined Tie2 activation status in VM and found activated receptor in lesional and non-lesional vessels. To gain insight into functional effects of VM mutant Tie2, wild-type and R849W mutant receptor were expressed in cultured human venous endothelial cells. Mutant Tie2 was constitutively phosphorylated in endothelial cells in vivo and caused a marked suppression of apoptosis. The anti-apoptotic kinase Akt was constitutively activated in cells expressing mutant receptor. Dominant-negative Akt inhibited the pro-survival activity of mutant Tie2. Migration of smooth muscle cells induced by conditioned medium from cells expressing mutant receptor was similar to that from cells expressing wild-type receptor. These data suggest that a primary effect of R849W Tie2 in VM is to allow survival of mural cell poor vessels via ligand-independent Tie2 activation of Akt and endothelial survival, rather than to directly induce formation of dysmorphogenic vessels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526080     DOI: 10.1007/s00109-004-0601-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  27 in total

1.  Antiproliferative effect of UTP on human arterial and venous smooth muscle cells.

Authors:  P J White; R Kumari; K E Porter; N J London; L L Ng; M R Boarder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-12       Impact factor: 4.733

2.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues.

Authors:  A L Wong; Z A Haroon; S Werner; M W Dewhirst; C S Greenberg; K G Peters
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway.

Authors:  I Kim; H G Kim; J N So; J H Kim; H J Kwak; G Y Koh
Journal:  Circ Res       Date:  2000 Jan 7-21       Impact factor: 17.367

5.  Allelic and locus heterogeneity in inherited venous malformations.

Authors:  J T Calvert; T J Riney; C D Kontos; E H Cha; V G Prieto; C R Shea; J N Berg; N C Nevin; S A Simpson; K A Pasyk; M C Speer; K G Peters; D A Marchuk
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

6.  Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.

Authors:  J R Gamble; J Drew; L Trezise; A Underwood; M Parsons; L Kasminkas; J Rudge; G Yancopoulos; M A Vadas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

7.  Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

Authors:  A Papapetropoulos; G García-Cardeña; T J Dengler; P C Maisonpierre; G D Yancopoulos; W C Sessa
Journal:  Lab Invest       Date:  1999-02       Impact factor: 5.662

8.  Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response.

Authors:  E I Korpelainen; M Kärkkäinen; Y Gunji; M Vikkula; K Alitalo
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

9.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.

Authors:  L E Benjamin; I Hemo; E Keshet
Journal:  Development       Date:  1998-05       Impact factor: 6.868

View more
  14 in total

1.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

Review 2.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

3.  Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB.

Authors:  Melanie Uebelhoer; Marjut Nätynki; Jaakko Kangas; Antonella Mendola; Ha-Long Nguyen; Julie Soblet; Catherine Godfraind; Laurence M Boon; Lauri Eklund; Nisha Limaye; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2013-04-30       Impact factor: 6.150

4.  Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations.

Authors:  J Soblet; N Limaye; M Uebelhoer; L M Boon; M Vikkula
Journal:  Mol Syndromol       Date:  2013-03-26

Review 5.  Cerebral cavernous malformation: new molecular and clinical insights.

Authors:  N Revencu; M Vikkula
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

6.  Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.

Authors:  Denise M Adams; Cameron C Trenor; Adrienne M Hammill; Alexander A Vinks; Manish N Patel; Gulraiz Chaudry; Mary Sue Wentzel; Paula S Mobberley-Schuman; Lisa M Campbell; Christine Brookbank; Anita Gupta; Carol Chute; Jennifer Eile; Jesse McKenna; Arnold C Merrow; Lin Fei; Lindsey Hornung; Michael Seid; A Roshni Dasgupta; Belinda H Dickie; Ravindhra G Elluru; Anne W Lucky; Brian Weiss; Richard G Azizkhan
Journal:  Pediatrics       Date:  2016-01-18       Impact factor: 7.124

Review 7.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

8.  Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Authors:  Elisa Boscolo; Nisha Limaye; Lan Huang; Kyu-Tae Kang; Julie Soblet; Melanie Uebelhoer; Antonella Mendola; Marjut Natynki; Emmanuel Seront; Sophie Dupont; Jennifer Hammer; Catherine Legrand; Carlo Brugnara; Lauri Eklund; Miikka Vikkula; Joyce Bischoff; Laurence M Boon
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

9.  Ligand-independent Tie2 dimers mediate kinase activity stimulated by high dose angiopoietin-1.

Authors:  Daishi Yamakawa; Hiroyasu Kidoya; Susumu Sakimoto; Weizhen Jia; Hisamichi Naito; Nobuyuki Takakura
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

10.  Somatic PIK3CA mutations as a driver of sporadic venous malformations.

Authors:  Pau Castel; F Javier Carmona; Joaquim Grego-Bessa; Michael F Berger; Agnès Viale; Kathryn V Anderson; Silvia Bague; Maurizio Scaltriti; Cristina R Antonescu; Eulàlia Baselga; José Baselga
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.